These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 31863599)
1. FGF23 and the PTH response to paricalcitol in chronic kidney disease. D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599 [TBL] [Abstract][Full Text] [Related]
2. Serum phosphate modifies the vascular response to vitamin D receptor activation in chronic kidney disease (CKD) patients. Zoccali C; Torino C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Ghiadoni L; Thadhani R; Tripepi G; Mallamaci F Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):581-589. PubMed ID: 27113290 [TBL] [Abstract][Full Text] [Related]
3. Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. Spoto B; Pizzini P; Tripepi G; Mallamaci F; Zoccali C Nephrol Dial Transplant; 2018 Oct; 33(10):1764-1769. PubMed ID: 29304245 [TBL] [Abstract][Full Text] [Related]
4. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease. Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277 [TBL] [Abstract][Full Text] [Related]
6. Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels. Torino C; Pizzini P; Cutrupi S; Tripepi G; Mallamaci F; Thadhani R; Zoccali C Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):260-266. PubMed ID: 28017524 [TBL] [Abstract][Full Text] [Related]
7. Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5. Gravesen E; Hofman-Bang J; Lewin E; Olgaard K Scand J Clin Lab Invest; 2013 Mar; 73(2):107-16. PubMed ID: 23281842 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor activation by paricalcitol and insulin resistance in CKD. Spoto B; Pizzini P; Cutrupi S; Tripepi G; Curatola G; Mallamaci F; Zoccali C Nutr Metab Cardiovasc Dis; 2018 Mar; 28(3):291-297. PubMed ID: 29307660 [TBL] [Abstract][Full Text] [Related]
9. Paricalcitol and endothelial function in chronic kidney disease trial. Zoccali C; Curatola G; Panuccio V; Tripepi R; Pizzini P; Versace M; Bolignano D; Cutrupi S; Politi R; Tripepi G; Ghiadoni L; Thadhani R; Mallamaci F Hypertension; 2014 Nov; 64(5):1005-11. PubMed ID: 25259743 [TBL] [Abstract][Full Text] [Related]
10. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Taal MW; Thurston V; McIntyre NJ; Fluck RJ; McIntyre CW Kidney Int; 2014 Aug; 86(2):407-13. PubMed ID: 24429404 [TBL] [Abstract][Full Text] [Related]
11. Paricalcitol regulatory effect on inflammatory, fibrotic and anticalcificating parameters in renal patiente. Far beyond mineral bone disease regulation. Salanova Villanueva L; Gil Giraldo Y; Santos Sánchez-Rey B; Aguilera Peralta A Nefrologia (Engl Ed); 2020; 40(2):171-179. PubMed ID: 31740151 [TBL] [Abstract][Full Text] [Related]
12. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895 [TBL] [Abstract][Full Text] [Related]
13. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats. Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797 [TBL] [Abstract][Full Text] [Related]
14. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption. Phelps KR; Mason DL Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023 [TBL] [Abstract][Full Text] [Related]
15. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease. Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550 [TBL] [Abstract][Full Text] [Related]
16. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease . Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871 [TBL] [Abstract][Full Text] [Related]
17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251 [TBL] [Abstract][Full Text] [Related]